News | Vena Cava Filters | September 26, 2017

One-Year SENTRY Data Presented at VIVA

Bioconvertible inferior vena cava shows no new incidence of pulmonary embolism through 12 months

September 26, 2017 — The one-year results of the SENTRY clinical trial were presented by principal investigator Michael Dake, M.D., Stanford University, at the VIVA Physicians’ congress, Sept. 11-14 in Las Vegas. 

SENTRY is a prospective, single-arm, multi-center registry trial in which the safety and effectiveness of Novate Medical’s Sentry inferior vena cava (IVC) filter, the world’s first bioconvertible IVC filter, was studied. The Sentry is a new generation of IVC filter designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, obviating the need to retrieve and addressing the typical filter-related complications of existing IVC filters. One hundred twenty-nine patients requiring temporary protection against PE were enrolled across 23 sites in the U.S., Europe and Chile. The rate of new symptomatic PE through 12 months was 0 percent (0/129). There were no instances of filter tilting, migration, embolization, fracture, or IVC perforation through 12 months, and there were no filter-related deaths. The rate of successful filter bioconversion was 95.7 percent (110/115) at six months and 96.4 percent (106/110) at 12 months; this is higher than the majority of published IVC filter retrieval rates.

The Sentry IVC filter received U.S. Food and Drug Administration (FDA) 510(k) clearance in February 2017.

Dake commented, “The SENTRY one-year results are compelling; a 0 percent PE rate and no filter-related complications show that the Sentry IVC filter represents an important new development in the prevention of PE.”

For more information: www.novatemedical.com


Related Content

News | Vena Cava Filters

July 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to a laser ...

Home July 27, 2021
Home
News | Vena Cava Filters

September 9, 2020 — The Society of Interventional Radiology (SIR) published new clinical practice guidelines that ...

Home September 09, 2020
Home
News | Vena Cava Filters

December 4, 2018 — BTG plc announced the first patients outside of a clinical trial have been successfully implanted ...

Home December 04, 2018
Home
News | Vena Cava Filters

January 2, 2018 — Osborne & Associates Law Firm, P.A., of Boca Raton, Fla., has filed suit in Palm Beach Circuit Court ...

Home January 02, 2018
Home
Videos | Vena Cava Filters

This video, provided by Crux Biomedical, demonstrates the implantation of the FDA-cleared Crux VCF inferior vena cava ...

Home July 24, 2012
Home
Videos | Vena Cava Filters

The Crux inferior vena cava (IVC) filter was designed for easy deployment and later retrieval. This video clip shows ...

Home April 06, 2012
Home
Videos | Vena Cava Filters

The Crux inferior vena cava (IVC) filter was designed for easy deployment and later retrival. This video clip shows ...

Home April 06, 2012
Home
Subscribe Now